XLS Stock Overview
Focuses on the development and commercialization of technologies in the life sciences sector. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Xlife Sciences AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 21.20 |
| 52 Week High | CHF 51.00 |
| 52 Week Low | CHF 20.30 |
| Beta | 0.44 |
| 1 Month Change | -11.30% |
| 3 Month Change | -11.67% |
| 1 Year Change | -54.31% |
| 3 Year Change | -54.16% |
| 5 Year Change | n/a |
| Change since IPO | -54.16% |
Recent News & Updates
Shareholder Returns
| XLS | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 0.5% | 2.3% | -0.03% |
| 1Y | -54.3% | 24.0% | 10.7% |
Return vs Industry: XLS underperformed the Swiss Life Sciences industry which returned 26.1% over the past year.
Return vs Market: XLS underperformed the Swiss Market which returned 9.7% over the past year.
Price Volatility
| XLS volatility | |
|---|---|
| XLS Average Weekly Movement | 10.2% |
| Life Sciences Industry Average Movement | 4.1% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in CH Market | 8.3% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: XLS's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: XLS's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 17 | Oliver Baumann | www.xlifesciences.ch |
Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences sector. The company’s project consists of technology platforms that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also engages in developing mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases; researching, developing, and manufacturing chemical and active pharmaceutical ingredients for human and veterinary medicines; and early identification kidney diseases.
Xlife Sciences AG Fundamentals Summary
| XLS fundamental statistics | |
|---|---|
| Market cap | CHF 121.73m |
| Earnings (TTM) | CHF 21.24m |
| Revenue (TTM) | CHF 990.27k |
5.7x
P/E Ratio122.9x
P/S RatioIs XLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XLS income statement (TTM) | |
|---|---|
| Revenue | CHF 990.27k |
| Cost of Revenue | CHF 450.93k |
| Gross Profit | CHF 539.34k |
| Other Expenses | -CHF 20.70m |
| Earnings | CHF 21.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Apr 25, 2025
| Earnings per share (EPS) | 3.70 |
| Gross Margin | 54.46% |
| Net Profit Margin | 2,144.50% |
| Debt/Equity Ratio | 15.0% |
How did XLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 02:50 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xlife Sciences AG is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Jelovcan | Stifel, Equities Research |
| Ulrich Huwald | Warburg Research GmbH |